$BMY (Bristol-Myers Squibb Company)

$BMY {{ '2015-07-23T18:50:22+0000' | timeago}} • Webcast

$BMY 2Q15 Q&A: Boris from SunTrust asked about thoughts around publication and presentation strategy along with regulatory strategy for renal cancer and update on hematology. Francis answered that BMY is working with investigators on future publication results. BMY can work with health authorities and looking to submit data as soon as possible.

$ABBV {{ '2017-09-22T11:48:04+0000' | timeago}} • Announcement

$ABBV and $BMY announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).

$BMY {{ '2017-09-22T11:37:45+0000' | timeago}} • Announcement

$BMY announced that Japan Ministry of Health, Labor and Welfare approved 'Opdivo.' The nivolumab drug is used in the treatment of patients with unresectable advanced or recurrent gastric cancer progressing after chemotherapy.

$BMY {{ '2017-09-13T20:46:25+0000' | timeago}} • Announcement

$BMY declared a quarterly dividend of $0.39 per share on the $.10 par value common stock of the corporation. The next quarterly dividend will be payable on November 1, 2017, to stockholders of record at the close of business on October 6, 2017.

$BMY {{ '2017-09-13T20:29:36+0000' | timeago}} • Announcement

$BMY elected Karen Vousden, effective Jan 1, 2018. to serve as a member of the Science and Technology Committee of the Board of Directors. Dr. Vousden is currently group leader at the Francis Crick Institute in London and the Chief Scientist at Cancer Research UK.

$BMY {{ '2017-09-11T10:59:32+0000' | timeago}} • Announcement

$BMY said Opdivo plus Yervoy combination demonstrated superior overall survival and showed durable responses in patients with previously untreated advanced or metastatic renal cell carcinoma in phase 3 CheckMate -214 trial. The combination lowered the risk of death by 37% and improved overall survival in all randomized patients.

$BMY {{ '2017-09-07T13:34:21+0000' | timeago}} • Announcement

$BMY said a Phase 3 study evaluating Opdivo plus Yervoy in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) met its co-primary endpoint. This demonstrates superior overall survival (OS) compared to sunitinib in intermediate- and poor-risk patients.

$PFE {{ '2017-08-29T14:05:59+0000' | timeago}} • Announcement

$PFE and $BMY presented investigational Eliquis data for patients with non-valvular atrial fibrillation undergoing cardioversion. The outcomes measured in EMANATE, a Phase 4 clinical trial, were the occurrence of acute stroke, systemic embolism, major bleeding, clinically relevant non-major bleeding and all-cause death.

$BMY {{ '2017-08-01T15:10:47+0000' | timeago}} • Announcement

$BMY received FDA approval for Opdivo (nivolumab) injection in microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a Fluoropyrimidine, Oxaliplatin, and Irinotecan.

$BMY {{ '2017-07-27T12:44:31+0000' | timeago}} • Infographic

$BMY Bristol-Myers Squibb Co Earnings AlphaGraphics: Q2 2017 highlights

$BMY {{ '2017-07-27T11:32:39+0000' | timeago}} • Announcement

$BMY updated its FY17 GAAP EPS guidance range to $2.66-2.76 and raised the lower end of its non-GAAP EPS guidance range to $2.90-3.00, as the pharma giant posted 2Q17 results.

$BMY {{ '2017-07-27T11:30:29+0000' | timeago}} • Announcement

As $BMY posted its 2Q17 results, it also announced that the European Commission (EC) approved its drug ORENCIA alone or in combination with methotrexate for the treatment of active Psoriatic Arthritis in certain adult patients.

$BMY {{ '2017-07-27T11:28:03+0000' | timeago}} • Announcement

A 31% surge in R&D expenses of $1.7Bil in 2Q17 saw $BMY's net attributable earnings slumping 24% to $916MM, even as revenue rose 6% to $5.1Bil. Diluted EPS slipped 19% to $0.56, while non-GAAP diluted EPS rose 7% to $0.74.

$BMY {{ '2017-07-25T15:05:20+0000' | timeago}} • Announcement

The FDA has accepted $BMY's supplemental Biologics License Applications to update Opdivo dosing to include 480 mg infused over 30 minutes every four weeks for all currently approved monotherapy indications. The applications are under review with an action date of March 5, 2018. Opdivo has become important treatment option across multiple cancers.

$BMY {{ '2017-07-24T16:32:02+0000' | timeago}} • Announcement

$BMY said the U.S. Food and Drug Administration (FDA) has expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.

$BMY {{ '2017-07-10T11:35:22+0000' | timeago}} • Announcement

$BMY said the FDA accepted its supplemental New Drug Application (sNDA) to include an indication for Sprycel (dasatinib) to treat children with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia, as well as a powder for oral suspension formulation of Sprycel.

$BMY {{ '2017-06-26T11:44:11+0000' | timeago}} • Announcement

$BMY said, in its Phase 3 study, Empliciti plus lenalidomide/dexamethasone continued to demonstrate efficacy in patients with plasma cell cancer, compared to patients treated with lenalidomide/dexamethasone alone. The combination therapy demonstrated a sustained reduction in risk of progression/death of 29%.

$BMY {{ '2017-06-21T11:54:13+0000' | timeago}} • Announcement

$BMY announced expiration on June 20 of its cash tender offer for any and all of certain of its outstanding debt securities. About $337MM of the notes were validly tendered and not validly withdrawn on or prior to June 20, 2017, and an additional $106,000 of the notes had been submitted pursuant to a Notice of Guaranteed Delivery.

$SGEN {{ '2017-06-15T12:21:22+0000' | timeago}} • Announcement

Pharma firms $SGEN and $BMY presented an interim analysis from the phase 1/2 clinical trial of  lymphoma drugs Adcetris and Opdivo in relapsed or refractory classical Hodgkin lymphoma, at the International Conference on Malignant Lymphoma in Switzerland. The drugs have not been approved, in combination, for the condition or for other indications.

$BMY {{ '2017-06-14T13:11:26+0000' | timeago}} • Announcement

$BMY commenced a cash tender offer for any and all of its 5.875% Notes due 2036, 6.125% Notes due 2038 and 6.875% Debentures due 2097. The expiration date of the tender offer is June 20, 2017, unless extended or earlier terminated.

$BMY {{ '2017-06-13T20:19:24+0000' | timeago}} • Announcement

$BMY's BoD declared a quarterly dividend of $0.50 per share on the $2 Convertible Preferred Stock, payable September 1, 2017 to stockholders of record on August 8, 2017.

Recent Transcripts

LCI (Lannett Company, Inc.)
Wednesday, August 23 2017 - 8:30pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
ARRY (Array BioPharma Inc.)
Wednesday, August 9 2017 - 1:00pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
MNK (Mallinckrodt Public Limited Company)
Tuesday, August 8 2017 - 12:30pm
CBM (Cambrex Corporation.)
Friday, August 4 2017 - 12:30pm
MSA (MSA Safety Incorporated)
Friday, August 4 2017 - 12:30pm
EBS (Emergent BioSolutions, Inc.)
Thursday, August 3 2017 - 9:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
MOH (Molina Healthcare, Inc.)
Wednesday, August 2 2017 - 9:00pm
RIGL (Rigel Pharmaceuticals, Inc.)
Tuesday, August 1 2017 - 9:00pm
ILMN (Illumina Inc.)
Tuesday, August 1 2017 - 8:30pm
MD (MEDNAX, Inc.)
Friday, July 28 2017 - 2:00pm
MRK (Merck & Co. Inc.)
Friday, July 28 2017 - 12:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, July 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
RDY (Dr. Reddy's Laboratories Ltd.)
Thursday, July 27 2017 - 1:00pm
MCK (McKesson Corporation)
Thursday, July 27 2017 - 12:30pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm

AlphaGraphics you may like